
Novo Nordisk is preparing to start a phase III study of hemophilia drug Mim8, Clinicaltrials.gov data shows.
Mim8 is a new medicine for the prevention of bleeding episodes, which functions by replacing coagulation factor VIII, which is lacking in hemophiliacs.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app